Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-Current DebtShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Change in Account Payables: 2012-2025

Historic Change in Account Payables for Ascendis Pharma A (ASND) over the last 12 years, with Sep 2025 value amounting to -$8.8 million.

  • Ascendis Pharma A's Change in Account Payables fell 7.49% to -$8.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.6 million, marking a year-over-year increase of 144.52%. This contributed to the annual value of $29.2 million for FY2024, which is 663.88% up from last year.
  • As of Q3 2025, Ascendis Pharma A's Change in Account Payables stood at -$8.8 million, which was down 151.13% from $17.2 million recorded in Q2 2025.
  • Over the past 5 years, Ascendis Pharma A's Change in Account Payables peaked at $51.2 million during Q3 2021, and registered a low of -$42.9 million during Q1 2025.
  • Its 3-year average for Change in Account Payables is -$215,390, with a median of -$5.4 million in 2023.
  • Data for Ascendis Pharma A's Change in Account Payables shows a peak YoY increase of 544.50% (in 2024) and a maximum YoY decrease of 275.44% (in 2024) over the last 5 years.
  • Ascendis Pharma A's Change in Account Payables (Quarterly) stood at -$17.3 million in 2021, then skyrocketed by 238.15% to $23.9 million in 2022, then slumped by 145.28% to -$10.8 million in 2023, then skyrocketed by 544.50% to $48.1 million in 2024, then fell by 7.49% to -$8.8 million in 2025.
  • Its last three reported values are -$8.8 million in Q3 2025, $17.2 million for Q2 2025, and -$42.9 million during Q1 2025.